相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design
Jeffrey S. Ross et al.
ONCOLOGIST (2021)
Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type
Jim Abraham et al.
TRANSLATIONAL ONCOLOGY (2021)
Context is everything: aneuploidy in cancer
Uri Ben-David et al.
NATURE REVIEWS GENETICS (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour -agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions
T. Yoshino et al.
ANNALS OF ONCOLOGY (2020)
Different response to ALK inhibitors in EML4-ALK positive mediastinal cancer of unknown primary.
Chunhong Hu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Utility of circulating cell-free DNA (cfDNA) analysis in patients with carcinoma of unknown primary (CUP) in identifying alterations with strong evidence for response or resistance to targeted therapy.
Caroline Weipert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.
Junko Tanizaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
NOMINATOR: Feasibility of genomic testing of rare cancers to match cancer to treatment.
Damien Kee et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Mechanisms generating cancer genome complexity from a single cell division error
Neil T. Umbreit et al.
SCIENCE (2020)
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
Aditi P. Singh et al.
CANCERS (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Molecular screening to select therapy for advanced cancer?
I. F. Tannock et al.
ANNALS OF ONCOLOGY (2019)
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial
O. Tredan et al.
ANNALS OF ONCOLOGY (2019)
Promises, promises, and precision medicine
Michael J. Joyner et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Carcinoma of Unknown Primary with EML4-ALK Fusion Response to ALK Inhibitors
Peng Zhao et al.
ONCOLOGIST (2019)
Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation
Jing-hao Yao et al.
ONCOTARGETS AND THERAPY (2019)
The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity
Andrea E. Tijhuis et al.
MOLECULAR CYTOGENETICS (2019)
Tumor Mutation Burden-From Hopes to Doubts
Alfredo Addeo et al.
JAMA ONCOLOGY (2019)
Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?
Tilmann Bochtler et al.
FRONTIERS IN ONCOLOGY (2019)
Clinical and immune profiling for cancer of unknown primary site
Koji Haratani et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
K. Fizazi et al.
ANNALS OF ONCOLOGY (2019)
2037PA challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience
C Pauli et al.
ANNALS OF ONCOLOGY (2019)
Arcagen: An EORTC-SPECTA project to perform a molecular characterization of rare cancers: Results of the retrospective feasibility cohort
M. Vinches et al.
ANNALS OF ONCOLOGY (2019)
Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'
Alicia-Marie Conway et al.
BRITISH JOURNAL OF CANCER (2019)
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Cinta Hierro et al.
CLINICAL CANCER RESEARCH (2019)
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site
Hidetoshi Hayashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Prospective analysis of 895 patients on a UK Genomics Review Board
David Allan Moore et al.
ESMO OPEN (2019)
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Mark Yarchoan et al.
JCI INSIGHT (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
Katherine A. Hoadley et al.
CELL (2018)
Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy
Zoran Gatalica et al.
EUROPEAN JOURNAL OF CANCER (2018)
Genetic characterisation of molecular targets in carcinoma of unknown primary
B. Clynick et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Determinants and clinical implications of chromosomal instability in cancer
Laurent Sansregret et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling
Carmen Binder et al.
CANCER MEDICINE (2018)
Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival
Henrik Hornshoj et al.
NPJ GENOMIC MEDICINE (2018)
The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment
Samuel F. Bakhoum et al.
CELL (2018)
Precision oncology: separating the wheat from the chaff
Jordi Remon et al.
ESMO OPEN (2018)
Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+NSCLC Patients
Marcin Kowanetz et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary
Sebastian Moran et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
Teresa Davoli et al.
SCIENCE (2017)
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
A. M. Varghese et al.
ANNALS OF ONCOLOGY (2017)
Putting p53 in Context
Edward R. Kastenhuber et al.
CELL (2017)
Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary
Shumei Kato et al.
CANCER RESEARCH (2017)
The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome
Deborah R. Caswell et al.
BMC MEDICINE (2017)
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)
H. H. Yoon et al.
ANNALS OF ONCOLOGY (2016)
A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site
Dong-Yeop Shin et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Spontaneous regression of tumour and the role of microbial infection - possibilities for cancer treatment
Petra Kucerova et al.
ANTI-CANCER DRUGS (2016)
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis
Sebastian Moran et al.
LANCET ONCOLOGY (2016)
Chromosome instability drives phenotypic switching to metastasis
ChongFeng Gao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Molecular driver alterations and their clinical relevance in cancer of unknown primary site
Harald Loeffler et al.
ONCOTARGET (2016)
Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Integration o genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification
Stefan Groeschel et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2016)
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
K. Fizazi et al.
ANNALS OF ONCOLOGY (2015)
Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin
Jonas Vikesa et al.
BMC CANCER (2015)
Paclitaxel/Carboplatin With or Without Belinostat as Empiric First-Line Treatment for Patients With Carcinoma of Unknown Primary Site: A Randomized, Phase 2 Trial
John D. Hainsworth et al.
CANCER (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps
Young E. Whang et al.
JAMA ONCOLOGY (2015)
Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps
Erin F. Cobain et al.
JAMA ONCOLOGY (2015)
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site New Routes to Targeted Therapies
Jeffrey S. Ross et al.
JAMA ONCOLOGY (2015)
Cancer of unknown primary: time trends in incidence, United States
Elena Mnatsakanyan et al.
CANCER CAUSES & CONTROL (2014)
Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961-2010
David H. Brewster et al.
CANCER EPIDEMIOLOGY (2014)
Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group
G. Pentheroudakis et al.
CLINICAL & EXPERIMENTAL METASTASIS (2014)
Cancer of Unknown Primary Site
Gauri R. Varadhachary et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles
Lauren M. Zasadil et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary
Norma A. Palma et al.
CASE REPORTS IN ONCOLOGY (2014)
A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib
Jon H. Chung et al.
CASE REPORTS IN ONCOLOGY (2014)
Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer
Matias Riihimaeki et al.
BMC CANCER (2013)
Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis
J. Lee et al.
BRITISH JOURNAL OF CANCER (2013)
Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities
D. Urban et al.
BRITISH JOURNAL OF CANCER (2013)
Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors
George Pentheroudakis et al.
CLINICAL & EXPERIMENTAL METASTASIS (2013)
Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks
Konstantinos Kamposioras et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2013)
Molecular Profiling for Druggable Genetic Abnormalities in Carcinoma of Unknown Primary
Daniel S-W. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute
John D. Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary
Richard W. Tothill et al.
JOURNAL OF PATHOLOGY (2013)
Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology
F. Anthony Greco et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
A Retrospective Study of Treatment Outcomes in Patients With Carcinoma of Unknown Primary Site and a Colorectal Cancer Molecular Profile
John D. Hainsworth et al.
CLINICAL COLORECTAL CANCER (2012)
Management of unfavourable carcinoma of unknown primary site: Synthesis of recent literature
Eric Yaovi Amela et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial
M. Gross-Goupil et al.
EUROPEAN JOURNAL OF CANCER (2012)
A DNA methylation fingerprint of 1628 human samples
Agustin F. Fernandez et al.
GENOME RESEARCH (2012)
Chromosomal instability and cancer: a complex relationship with therapeutic potential
Samuel F. Bakhoum et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Cancer of unknown primary site
Nicholas Pavlidis et al.
LANCET (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Chromosomal Instability Confers Intrinsic Multidrug Resistance
Alvin J. X. Lee et al.
CANCER RESEARCH (2011)
Prospective Gene Signature Study Using microRNA to Identify the Tissue of Origin in Patients with Carcinoma of Unknown Primary
Gauri R. Varadhachary et al.
CLINICAL CANCER RESEARCH (2011)
MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin
Manuela Ferracin et al.
JOURNAL OF PATHOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Paclitaxel/Carboplatin/Etoposide Versus Gemcitabine/Irinotecan in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site A Randomized, Phase III Sarah Cannon Oncology Research Consortium Trial
John D. Hainsworth et al.
CANCER JOURNAL (2010)
Mechanisms of Chromosomal Instability
Sarah L. Thompson et al.
CURRENT BIOLOGY (2010)
Proliferation of aneuploid human cells is limited by a p53-dependent mechanism
Sarah L. Thompson et al.
JOURNAL OF CELL BIOLOGY (2010)
Cancer patients without a known primary: Incidence and survival trends in Sweden 1960-2007
Margareta Randen et al.
ACTA ONCOLOGICA (2009)
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial
G. Huebner et al.
BRITISH JOURNAL OF CANCER (2009)
Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis
Vassilis Golfinopoulos et al.
CANCER TREATMENT REVIEWS (2009)
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
Lee M. Ellis et al.
CLINICAL CANCER RESEARCH (2009)
Implementation of a novel microarray-based diagnostic test for cancer of unknown primary
Ryan K. van Laar et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site
John D. Hainsworth et al.
ONCOLOGIST (2009)
Parallel progression of primary tumours and metastases
Christoph A. Klein
NATURE REVIEWS CANCER (2009)
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation
Gauri R. Varadhachary et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary
Hugo M. Horlings et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: The Minnie Pearl Cancer Research Network
John D. Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Switching benchmarks in cancer of unknown primary: From autopsy to microarray
George Pentheroudakis et al.
EUROPEAN JOURNAL OF CANCER (2007)
Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site - Results of an Italian multicenter, randomized, phase II study
Sergio Palmeri et al.
CANCER (2006)
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers
Scott L. Carter et al.
NATURE GENETICS (2006)
Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells
T Fujiwara et al.
NATURE (2005)
An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin
RW Tothill et al.
CANCER RESEARCH (2005)
Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint
GJPL Kops et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site:: Results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)
S Culine et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary
L Assersohn et al.
EUROPEAN JOURNAL OF CANCER (2003)
Cytogenetic profile of unknown primary tumors: Clues for their pathogenesis and clinical management
D Pantou et al.
NEOPLASIA (2003)
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site
S Culine et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site
AG Macdonald et al.
BRITISH JOURNAL OF CANCER (2002)
分享论文
